Diabetic Gastroparesis Treatment Market Report 2026

The diabetic gastroparesis treatment market size has grown strongly in recent years. It will grow from $4.05 billion in 2025 to $4.28 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising diabetes complications, limited historical treatment options, increasing diagnosis rates, reliance on pharmacological management, growth in gastroenterology specialty care.

The diabetic gastroparesis treatment market size is expected to see strong growth in the next few years. It will grow to $5.47 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to development of novel prokinetic agents, increased disease awareness, expansion of specialty clinics, demand for long-term symptom control, innovation in gastric stimulation technologies. Major trends in the forecast period include increasing use of prokinetic drug therapies, rising focus on symptom-based disease management, expansion of combination pharmacological treatments, growing adoption of minimally invasive interventions, increased emphasis on dietary and lifestyle management.

The rising prevalence of diabetes is expected to drive the growth of the diabetic gastroparesis treatment market in the coming years. Diabetes prevalence refers to the proportion of the population diagnosed with diabetes at a given time. Diabetic gastroparesis treatment is primarily used to manage symptoms and complications associated with this condition, which is a common complication of diabetes. For instance, in April 2025, according to the International Diabetes Federation, a Belgium-based international non-profit organization representing national diabetes associations, approximately 589 million adults aged 20-79 were living with diabetes worldwide, a number projected to increase to 853 million by 2050. Therefore, the growing prevalence of diabetes is supporting the expansion of the diabetic gastroparesis treatment market.

The increasing number of surgical procedures is also expected to propel the growth of the diabetic gastroparesis treatment market going forward. Surgery is a branch of medicine that involves operative procedures to treat diseases, injuries, or medical conditions. Certain surgical procedures performed in diabetic patients can lead to post-surgical gastroparesis, including Nissen fundoplication, gastrectomy, gastric bypass surgery, pancreatectomy, vagotomy, and cholecystectomy, which may damage the vagus nerve responsible for coordinating food movement through the digestive tract. For instance, in June 2024, according to the American Society of Plastic Surgeons, a US-based non-profit professional organization, minimally invasive procedures grew by 7 percent in 2023, exceeding the growth rate of traditional surgical procedures by 2 percent. Therefore, the rising volume of surgical procedures is contributing to the growth of the diabetic gastroparesis treatment market.

Major companies operating in the diabetic gastroparesis treatment market are introducing advanced solutions to improve diagnostic precision and therapeutic outcomes. One such approach is small bowel intubation, which involves inserting a tube into the small intestine to enable accurate monitoring and targeted treatment in conditions such as diabetic gastroparesis, where gastric motility is impaired. For instance, in September 2024, Avenacy, a US-based pharmaceutical company, launched Metoclopramide Injection (USP) in the United States. This injectable medication is intended for multiple indications, including the relief of symptoms associated with diabetic gastroparesis. It helps prevent nausea and vomiting related to chemotherapy and surgical procedures, assists in small bowel intubation when standard methods fail to pass a tube through the pylorus, stimulates gastric emptying, and facilitates barium transit during radiological examinations.

Major companies operating in the diabetic gastroparesis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Ipca Laboratories Ltd., Abbott Laboratories, AstraZeneca plc, Medtronics plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Janssen Global Services LLC, Boston Scientific Corporation, Fresenius Kabi AG, Bausch Health Companies Inc., Salix Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Wockhardt Ltd., ANI Pharmaceuticals Inc., Endologic LLC, Vanda Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Theravance Biopharma Inc., Neurogastrx Inc., Evoke Pharma Inc., CinRx Pharma LLC.

North America was the largest region in the diabetic gastroparesis treatment market in 2025, and is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic gastroparesis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetic gastroparesis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diabetic gastroparesis treatment market by increasing costs of imported medications, gastric stimulation devices, and specialized surgical equipment. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported therapies, while Asia-Pacific faces higher access costs for advanced interventions. These tariffs are increasing overall treatment expenses. However, they are also encouraging domestic pharmaceutical manufacturing and localized medical device production.

The diabetic gastroparesis treatment market research report is one of a series of new reports that provides diabetic gastroparesis treatment market statistics, including diabetic gastroparesis treatment industry global market size, regional shares, competitors with a diabetic gastroparesis treatment market share, detailed diabetic gastroparesis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic gastroparesis treatment industry. This diabetic gastroparesis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetic gastroparesis treatment focuses on managing delayed gastric emptying in patients with diabetes, typically using medications such as prokinetics and antiemetics, along with dietary modifications or surgical interventions in severe cases. These treatments are intended to reduce symptoms including nausea, vomiting, and abdominal discomfort.

The primary treatments for diabetic gastroparesis include medication and surgery. Medications such as gastroprokinetic agents, antiemetic agents, and botulinum toxin are used to diagnose, treat, prevent, or relieve symptoms associated with the condition. These therapies are administered through oral and injectable routes for managing compensated gastroparesis and gastric failure. They are distributed via hospital pharmacies, retail pharmacies, and other channels and are used by hospitals, home care settings, specialty clinics, and others.

The diabetic gastroparesis treatment market consists of revenues earned by entities by providing services such as medical evaluation, medication management, dietary consultation, insulin adjustment, lifestyle modifications, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic gastroparesis treatment market also includes sales of metoclopramide, erythromycin, domperidone, promethazine, and ondansetron (Zofran). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.